Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
The SLEDAI was originally developed to determine disease activity in patients with lupus.
SLEDAI-2K was developed as a modification of SLEDAI in order to include persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences. Specifically SLEDAI-2K allows persistent active disease in alopecia, mucous membrane ulcers, rash, and proteinuria to be scored.
SLEDAI-2K was validated against the original SLEDAI as a predictor for mortality and as a measure of global disease activity. It was also found to be equivalent to SLEDAI in describing changes in disease activity from one visit to the next.
References
Gladman DD, Ibañez D, Urowitz MB.
Systemic lupus erythematosus disease activity index 2000.
J Rheumatol. 2002 Feb;29(2):288-91.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE.
The development and validation of the SLE Disease Activity Index (SLEDAI).
Arthritis Rheum 1992;35:630-40.
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email contact@qxmd.com